Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downs
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... first-of-its-kind antidepressant drug discovered by a Northwestern University professor ... antidepressant therapies has been shown to alleviate symptoms within ... last for about seven days from a single dose. ... for learning and memory -- a very different approach ...
... known how bacteria exposed to antibiotics for long periods will ... of their cells, for instance, or modifying the compounds so ... another possible mechanism of antibiotic "resistance" in soil. In a ... of Environmental Quality , a group of Canadian and ...
... 6 de dezembro de  2012 A Integrated ... com a certificação pelo FBI de sua novíssima ... da IB criou o novo produto usando a ... junto com um transistor de película fina (TFT). ...
Cached Biology News:New antidepressant acts very rapidly and is long lasting 2New antidepressant acts very rapidly and is long lasting 3Antibiotic-eating bug unearthed in soil 2Antibiotic-eating bug unearthed in soil 3Integrated Biometrics Apresenta Sherlock, o Menor, Mais Leve e Fino Sensor Appendix F Mobile ID 2
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... -- Naurex Inc., a biopharmaceutical company leveraging its unique ... central nervous system, today announced that Norbert Riedel ... at the 33 rd annual J.P. Morgan Healthcare ... p.m. PST on Tuesday, January 13, 2015, at the ... About Naurex Inc. ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... Leaf Venture Partners Commit To Purchase ... to $300 Million ... Debt, VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... pharmaceutical and,medical device company, today announced that Angiotech,s Board ...
... ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty,biopharmaceutical company, ... 2008, Results press release will be issued ... Investor meeting and conference call time: 14:30 ... and conference call:, Angus Russell, Chief Executive Officer, ...
... N.J., July 3 On June 27, 2008,GeneraMedix ... Drug,Administration (FDA) for its Epoprostenol for Injection 1.5 ... 1.5 mg is indicated for the long-term,intravenous treatment ... the scleroderma spectrum of disease in NYHA,Class III ...
Cached Biology Technology:Angiotech to Establish Separate Operating and Royalty Businesses 2Angiotech to Establish Separate Operating and Royalty Businesses 3Angiotech to Establish Separate Operating and Royalty Businesses 4Angiotech to Establish Separate Operating and Royalty Businesses 5Angiotech to Establish Separate Operating and Royalty Businesses 6Angiotech to Establish Separate Operating and Royalty Businesses 7Angiotech to Establish Separate Operating and Royalty Businesses 8Angiotech to Establish Separate Operating and Royalty Businesses 9Angiotech to Establish Separate Operating and Royalty Businesses 10Angiotech to Establish Separate Operating and Royalty Businesses 11Angiotech to Establish Separate Operating and Royalty Businesses 12Angiotech to Establish Separate Operating and Royalty Businesses 13Angiotech to Establish Separate Operating and Royalty Businesses 14Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg 2
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... polyclonal to ThPok ( Abpromise for all ... peptide conjugated to KLH derived from within residues ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: